Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPT vs MPR in Newly Diagnosed Multiple Myeloma
NCT00602641Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2008
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of lenalidomide, thalidomide in multiple myeloma (MM), sponsored by National Cancer Institute. Started Feb 2008; status: active, not recruiting.
02
Drugs
lenalidomidethalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00602641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00602641.